Literature DB >> 15352045

Endogenous sex hormones and subsequent breast cancer in premenopausal women.

Andrea Micheli1, Paola Muti, Giorgio Secreto, Vittorio Krogh, Elisabetta Meneghini, Elisabetta Venturelli, Sabina Sieri, Valeria Pala, Franco Berrino.   

Abstract

Because of large intra-individual variation in hormone levels, few studies have investigated the relation of serum sex hormones to breast cancer (BC) in premenopausal women. We prospectively studied this relation, adjusting for timing of blood sampling within menstrual cycle. Premenopausal women (5,963), recruited to the Hormones and Diet in the Etiology of Breast Tumors (ORDET) cohort study, provided a blood sample in the 20-24th day of their menstrual cycle. After 5.2 years of follow-up, 65 histologically confirmed BC cases were identified and matched individually to 4 randomly selected controls. Sera, stored at -80 degrees C, were assayed blindly for dehydroepiandrosterone sulfate, total and free testosterone (FT), androstenedione, androstanediol-glucoronide, progesterone, 17-OH-progesterone, sex hormone-binding globulin, follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Fifty-five cases had information for multivariate analyses. Compared to controls, BC cases had shorter cycles and intervals between blood sampling and bleeding, and lower LH and FSH. FT was significantly associated with BC risk: relative risk (RR; adjusted for age, body mass index and ovarian cycle variables) of highest vs. lowest tertile was 2.85 [95% confidence interval (CI) = 1.11-7.33, p for trend = 0.030]. Progesterone was inversely associated with adjusted RR for highest vs. lowest tertile of 0.40 (95% CI = 0.15-1.08, p for trend = 0.077), significantly so in women with regular menses, where adjusted RR was 0.12 (95% CI = 0.03-0.52, p for trend = 0.005). These findings support the hypothesis that ovarian hyperandrogenism associated with luteal insufficiency increases the risk of BC in premenopausal women. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15352045     DOI: 10.1002/ijc.20403

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  38 in total

1.  Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women.

Authors:  A Heather Eliassen; Donna Spiegelman; Xia Xu; Larry K Keefer; Timothy D Veenstra; Robert L Barbieri; Walter C Willett; Susan E Hankinson; Regina G Ziegler
Journal:  Cancer Res       Date:  2011-12-05       Impact factor: 12.701

2.  Reduction in Ki-67 in benign breast tissue of high-risk women with the lignan secoisolariciresinol diglycoside.

Authors:  Carol J Fabian; Bruce F Kimler; Carola M Zalles; Jennifer R Klemp; Brian K Petroff; Qamar J Khan; Priyanka Sharma; Kenneth D R Setchell; Xueheng Zhao; Teresa A Phillips; Trina Metheny; Jennifer R Hughes; Hung-Wen Yeh; Karen A Johnson
Journal:  Cancer Prev Res (Phila)       Date:  2010-08-19

3.  Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.

Authors:  Wenzhen Ge; Tess V Clendenen; Yelena Afanasyeva; Karen L Koenig; Claudia Agnoli; Louise A Brinton; Joanne F Dorgan; A Heather Eliassen; Roni T Falk; Göran Hallmans; Susan E Hankinson; Judith Hoffman-Bolton; Timothy J Key; Vittorio Krogh; Hazel B Nichols; Dale P Sandler; Minouk J Schoemaker; Patrick M Sluss; Malin Sund; Anthony J Swerdlow; Kala Visvanathan; Mengling Liu; Anne Zeleniuch-Jacquotte
Journal:  Int J Cancer       Date:  2018-02-08       Impact factor: 7.396

4.  Endogenous estrogen, testosterone and progesterone levels in relation to breast cancer risk.

Authors:  Susan E Hankinson; A Heather Eliassen
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-24       Impact factor: 4.292

5.  Dose-response effects of aerobic exercise on estrogen among women at high risk for breast cancer: a randomized controlled trial.

Authors:  Kathryn H Schmitz; Nancy I Williams; Despina Kontos; Susan Domchek; Knashawn H Morales; Wei-Ting Hwang; Lorita L Grant; Laura DiGiovanni; Domenick Salvatore; Desire' Fenderson; Mitchell Schnall; Mary Lou Galantino; Jill Stopfer; Mindy S Kurzer; Shandong Wu; Jessica Adelman; Justin C Brown; Jerene Good
Journal:  Breast Cancer Res Treat       Date:  2015-10-28       Impact factor: 4.872

Review 6.  Circulating sex steroids and breast cancer risk in premenopausal women.

Authors:  Susan E Hankinson; A Heather Eliassen
Journal:  Horm Cancer       Date:  2010-02-09       Impact factor: 3.869

7.  Objective habitual physical activity and estradiol levels in obese Latina adolescents.

Authors:  Lauren E Gyllenhammer; Amanda K Vanni; Courtney E Byrd-Williams; Marc Kalan; Leslie Bernstein; Jaimie N Davis
Journal:  J Phys Act Health       Date:  2012-10-04

8.  Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma.

Authors:  Cristina Riva; Emanuele Dainese; Giacomo Caprara; Paolo Cossu Rocca; Giovanni Massarelli; Tibor Tot; Carlo Capella; Vincenzo Eusebi
Journal:  Virchows Arch       Date:  2005-10-19       Impact factor: 4.064

9.  Association of sulfotransferase SULT1A1 with breast cancer risk: a meta-analysis of case-control studies with subgroups of ethnic and menopausal statue.

Authors:  Yiwei Jiang; Liheng Zhou; Tingting Yan; Zhenzhou Shen; Zhimin Shao; Jinsong Lu
Journal:  J Exp Clin Cancer Res       Date:  2010-07-21

10.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.